Share on StockTwits

Research Analysts’ ratings reiterations for Monday, April 14th:

BioScrip (NASDAQ:BIOS) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $7.50 price target on the stock. Zacks’ analyst wrote, “In the fourth quarter of 2013, BioScrip posted mixed numbers with an earnings miss and better-than-expected revenues. PBM business witnessed another quarter of downfall, dragged by lower discount cards revenue and the termination of a large contract. However, BioScrip continues to remain the third largest home infusion services provider. We are encouraged by the company’s strategic expansion plan through inorganic means which includes the recently added CarePoint and divestment of its Home Health business. In addition, we remain hopeful about the favorable industry trends across the U.S. which should boost the company’s growth momentum. However, looming reimbursement pressure and margin headwinds are growing worries. The competitive landscape is also tough with the presence of larger players. We, thus, remain Neutral on BioScrip.”

Exchange Income (TSE:EIF) had its outperform rating reiterated by analysts at Scotiabank. They currently have a C$26.00 price target on the stock.

Fastenal (NASDAQ:FAST) had its underperform rating reiterated by analysts at Zacks. The firm currently has a $45.00 price target on the stock. Zacks’ analyst wrote, “Fastenal rebounded in the first quarter 2014, as the company witnessed double digit sales increase in March. As a result, adjusted earnings of $0.38 per share surpassed the Zacks Consensus Estimate and the year-ago earnings also. The reported net sales increased 8.7% year over year, and also exceeded the Zacks Consensus Estimate. Though Fastenal witnessed softer sales in January and February due to harsh weather conditions, sales improved in March due to favorable timing of Easter. The company has been struggling with its top line for the past few quarters due to lower sales of its fasteners product line which were being hurt by end-market slowdown and broader economic uncertainty. Management is focusing on increasing headcount to drive near-term sales. However, these initiatives increase employee costs substantially and hurt margins further. Hence, it is yet to be seen if this rebound is sustainable in the upcoming quarters. We maintain our Underperform recommendation on the stock.”

Health Insurance Innovations (NASDAQ:HIIQ) had its strong-buy rating reiterated by analysts at Raymond James. Raymond James currently has a $15.00 price target on the stock.

Itau Unibanco Holding Sociedade Anonima (NASDAQ:ITUB) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $16.00 price target on the stock.

JPMorgan Chase & Co. (NYSE:JPM) had its buy rating reissued by analysts at Wells Fargo & Co.. The firm currently has a $5.50 price target on the stock.

JPMorgan Chase & Co. (NYSE:JPM) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $58.00 target price on the stock. Zacks’ analyst wrote, “JPMorgan failed to overcome the tough backdrop that banks have been facing since the year began and missed the Zacks Consensus Estimate. Lackluster consumer and corporate activities, weak trading volumes and sluggish mortgage banking dragged earnings this time around. Also, fundamental pressure from a low interest rate and slow loan growth made matters worse. While its prudent expense management was reflected in the non-interest expenses, pressure on the top line and higher-than-expected provision dominated. After analyzing the results, we are maintaining our long-term Neutral recommendation on the stock.”

Lumenis (NASDAQ:LMNS) had its buy rating reissued by analysts at Wells Fargo & Co.. They currently have a $0.53 price target on the stock.

Landec Corp. (NASDAQ:LNDC) had its outperform rating reissued by analysts at Northland Securities. Northland Securities currently has a $14.00 target price on the stock.

Metro Inc Cl A Sub V (NASDAQ:MTRAF) had its outperform rating reissued by analysts at RBC Capital.

Parkland Fuel Corp (TSE:PKI) had its sector perform rating reiterated by analysts at Scotiabank. Scotiabank currently has a C$20.50 target price on the stock.

Primerica (NYSE:PRI) had its strong-buy rating reaffirmed by analysts at Raymond James. Raymond James currently has a $52.00 target price on the stock.

Prudential Financial (NYSE:PRU) had its strong-buy rating reissued by analysts at Raymond James. The firm currently has a $101.00 target price on the stock.

Patterson-UTI Energy (NASDAQ:PTEN) had its buy rating reaffirmed by analysts at Deutsche Bank. Deutsche Bank currently has a $35.00 target price on the stock.

Quality Systems (NASDAQ:QSII) had its underweight rating reaffirmed by analysts at KeyCorp. They currently have a $14.00 target price on the stock.

Tech Data Corp (NASDAQ:TECD) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $64.00 price target on the stock.

Transglobe Energy (NYSE:TGA) had its tender rating reissued by analysts at Paradigm Capital.

ING US (NYSE:VOYA) had its outperform rating reissued by analysts at Raymond James. The firm currently has a $40.00 target price on the stock.

Wells Fargo & Co. (NYSE:WFC) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $50.00 price target on the stock. Zacks’ analyst wrote, “Wells Fargo & Company has reported earnings of $1.05 per share in first-quarter 2014. Results improved from earnings per share of $1.00 in the prior quarter and $0.92 in the year-ago quarter. Also, it beat the Zacks Consensus Estimate by $0.08. Results reflected growth in total loans and deposits amid a challenging economy and disciplined expense management. Moreover, a strong capital position and returns on assets and equity were tailwinds. However, the company experienced a fall in non-interest income. After reviewing the results, we are maintaining our Neutral recommendation on the shares. “

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.